Abraham Pinter - Publications

Affiliations: 
New York University, New York, NY, United States 
Area:
Molecular Biology, Microbiology Biology

110 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Ferrara F, Erasmus MF, D'Angelo S, Leal-Lopes C, Teixeira AA, Choudhary A, Honnen W, Calianese D, Huang D, Peng L, Voss JE, Nemazee D, Burton DR, Pinter A, Bradbury ARM. A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. Nature Communications. 13: 462. PMID 35075126 DOI: 10.1038/s41467-021-27799-z  0.307
2021 Tolbert WD, Nguyen DN, Tuyishime M, Crowley AR, Chen Y, Jha S, Goodman D, Bekker V, Mudrak SV, DeVico AL, Lewis GK, Theis JF, Pinter A, Moody MA, Easterhoff D, et al. Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s. Frontiers in Immunology. 12: 787603. PMID 35069563 DOI: 10.3389/fimmu.2021.787603  0.491
2021 Datta P, Ukey R, Bruiners N, Honnen W, Carayannopoulos MO, Reichman C, Choudhary A, Onyuka A, Handler D, Guerrini V, Mishra PK, Dewald HK, Lardizabal A, Lederer L, Leiser AL, ... ... Pinter A, et al. Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination. Journal of Immunological Methods. 113165. PMID 34634317 DOI: 10.1016/j.jim.2021.113165  0.305
2021 Datta P, Ukey R, Bruiners N, Honnen W, Carayannopoulos MO, Reichman C, Choudhary A, Onyuka A, Handler D, Guerrini V, Mishra PK, Dewald HK, Lardizabal A, Lederer L, Leiser AL, ... ... Pinter A, et al. Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection. Medrxiv : the Preprint Server For Health Sciences. PMID 34282427 DOI: 10.1101/2021.07.09.21260266  0.304
2021 Datta P, Ukey R, Bruiners N, Honnen W, Carayannopoulos MO, Reichman C, Choudhary A, Onyuka A, Handler D, Guerrini V, Mishra PK, Dewald HK, Lardizabal A, Lederer L, Leiser AL, ... ... Pinter A, et al. Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection. Medrxiv : the Preprint Server For Health Sciences. PMID 34282427 DOI: 10.1101/2021.07.09.21260266  0.304
2021 Xu C, Wang A, Geng K, Honnen W, Wang X, Bruiners N, Singh S, Ferrara F, D'Angelo S, Bradbury ARM, Gennaro ML, Liu D, Pinter A, Chang TL. Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms. Viruses. 13. PMID 34064066 DOI: 10.3390/v13060953  0.35
2020 Magni R, Rruga F, Alsaab F, Sharif S, Howard M, Espina V, Kim B, Lepene B, Lee G, Alayouni MA, Steinberg H, Araujo R, Kashanchi F, Riccardi F, Morreira S, ... ... Pinter A, et al. Lipoarabinomannan antigenic epitope differences in tuberculosis disease subtypes. Scientific Reports. 10: 13944. PMID 32811861 DOI: 10.1038/S41598-020-70669-9  0.416
2020 Broger T, Nicol M, Sigal G, Gotuzzo E, Zimmer AJ, Surtie S, Caceres-Nakiche T, Mantsoki A, Reipold EI, Székely R, Tsionsky M, van Heerden J, Plisova T, Chikamatsu K, Lowary TL, ... Pinter A, et al. Diagnostic accuracy of three urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients. The Journal of Clinical Investigation. PMID 32692731 DOI: 10.1172/Jci140461  0.314
2019 Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Ivanova Reipold E, Ward A, Barr DA, Macé A, Trollip A, Burton R, Ongarello S, Pinter A, Lowary TL, Boehme C, et al. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. The Lancet. Infectious Diseases. PMID 31155318 DOI: 10.1016/S1473-3099(19)30001-5  0.349
2018 Sigal GB, Pinter A, Lowary TL, Kawasaki M, Li A, Mathew A, Tsionsky M, Zheng RB, Plisova T, Shen K, Katsuragi K, Choudhary A, Honnen WJ, Nahid P, Denkinger CM, et al. A novel sensitive immunoassay targeting the MTX-Lipoarabinomannan epitope meets the WHO's performance target for Tuberculosis diagnosis. Journal of Clinical Microbiology. PMID 30257899 DOI: 10.1128/Jcm.01338-18  0.382
2018 Amin AG, De P, Spencer JS, Brennan PJ, Daum J, Andre BG, Joe M, Bai Y, Laurentius L, Porter MD, Honnen WJ, Choudhary A, Lowary TL, Pinter A, Chatterjee D. Detection of lipoarabinomannan in urine and serum of HIV-positive and HIV-negative TB suspects using an improved capture-enzyme linked immuno absorbent assay and gas chromatography/mass spectrometry. Tuberculosis (Edinburgh, Scotland). 111: 178-187. PMID 30029905 DOI: 10.1016/J.Tube.2018.06.004  0.383
2018 Choudhary A, Patel D, Honnen W, Lai Z, Prattipati RS, Zheng RB, Hsueh YC, Gennaro ML, Lardizabal A, Restrepo BI, Garcia-Viveros M, Joe M, Bai Y, Shen K, Sahloul K, ... ... Pinter A, et al. Characterization of the Antigenic Heterogeneity of Lipoarabinomannan, the Major Surface Glycolipid of, and Complexity of Antibody Specificities toward This Antigen. Journal of Immunology (Baltimore, Md. : 1950). PMID 29610143 DOI: 10.4049/Jimmunol.1701673  0.453
2018 Yates NL, deCamp AC, Korber BT, Liao HX, Irene C, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, et al. HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology. PMID 29386288 DOI: 10.1128/Jvi.01843-17  0.515
2017 Qualls ZM, Choudhary A, Honnen W, Prattipati R, Robinson JE, Pinter A. Identification of novel structural determinants in MW965 Env that regulate the neutralization phenotype and conformational masking potential of primary HIV-1 isolates. Journal of Virology. PMID 29237828 DOI: 10.1128/Jvi.01779-17  0.609
2017 Perez LG, Martinez DR, deCamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, et al. V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. Plos One. 12: e0180720. PMID 28678869 DOI: 10.1371/Journal.Pone.0180720  0.513
2017 Nabi R, Moldoveanu Z, Wei Q, Golub ET, Durkin HG, Greenblatt RM, Herold BC, Nowicki MJ, Kassaye S, Cho MW, Pinter A, Landay AL, Mestecky J, Kozlowski PA. Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. Plos One. 12: e0180245. PMID 28671952 DOI: 10.1371/Journal.Pone.0180245  0.57
2017 Bradley T, Pollara J, Santra S, Vandergrift N, Pittala S, Bailey-Kellogg C, Shen X, Parks R, Goodman D, Eaton A, Balachandran H, Mach LV, Saunders KO, Weiner JA, Scearce R, ... ... Pinter A, et al. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nature Communications. 8: 15711. PMID 28593989 DOI: 10.1038/Ncomms15711  0.501
2016 Tian J, López CA, Derdeyn CA, Jones MS, Pinter A, Korber B, Gnanakaran S. Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein. Plos Computational Biology. 12: e1005094. PMID 27716795 DOI: 10.1371/Journal.Pcbi.1005094  0.759
2016 Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, Beaumont D, Shen X, Yates NL, Pinter A, Tomaras GD, Ferrari G, Montefiori DC, Hu SL. Induction of heterologous Tier 2 HIV-1 neutralizing and cross-reactive V1/V2-specific antibodies in rabbits by prime-boost immunization. Journal of Virology. PMID 27440894 DOI: 10.1128/Jvi.00853-16  0.608
2014 Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. The Journal of Clinical Investigation. 124: 3879-90. PMID 25105367 DOI: 10.1172/Jci75539  0.412
2014 Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, ... ... Pinter A, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science Translational Medicine. 6: 228ra39. PMID 24648342 DOI: 10.1126/Scitranslmed.3007730  0.472
2014 Shmelkov E, Krachmarov C, Grigoryan AV, Pinter A, Statnikov A, Cardozo T. Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies. Plos One. 9: e89987. PMID 24587168 DOI: 10.1371/Journal.Pone.0089987  0.556
2014 Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. Plos One. 9: e87572. PMID 24504509 DOI: 10.1371/Journal.Pone.0087572  0.511
2014 Salomon A, Krachmarov C, Lai Z, Honnen W, Zingman BS, Sarlo J, Gorny MK, Zolla-Pazner S, Robinson JE, Pinter A. Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. Virology. 448: 363-74. PMID 24314667 DOI: 10.1016/J.Virol.2013.10.007  0.548
2014 Pavlakis GN, Li J, Valentin A, Jalah R, Patel V, Rosati M, Kulkarni V, Alicea C, Vargas-Inchaustegui DA, Guan Y, Venzon D, Sardesai N, Fouts TR, Pinter A, Robert-Guroff M, et al. DNA and Protein Co-immunization Improves the Magnitude, Longevity, and Mucosal Dissemination of Immune Responses Aids Research and Human Retroviruses. 30: A63-A64. DOI: 10.1089/Aid.2014.5115.Abstract  0.347
2013 Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O'Connell RJ, Ngauy V, ... ... Pinter A, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. Plos One. 8: e53629. PMID 23349725 DOI: 10.1371/Journal.Pone.0053629  0.492
2013 Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, ... ... Pinter A, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 38: 176-86. PMID 23313589 DOI: 10.1016/J.Immuni.2012.11.011  0.558
2013 Pinter A, Neubert T, Burkhart M, Irene C, Reichman C, Honnen WJ. E105 Exploring the role of conformational heterogeneity in the V1/V2 domain of HIV-1 gp120 on the immunological properties of Env immunogens Jaids Journal of Acquired Immune Deficiency Syndromes. 62: S53. DOI: 10.1097/01.Qai.0000429242.32158.E7  0.748
2012 Basu D, Kraft CS, Murphy MK, Campbell PJ, Yu T, Hraber PT, Irene C, Pinter A, Chomba E, Mulenga J, Kilembe W, Allen SA, Derdeyn CA, Hunter E. HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection. Retrovirology. 9: 76. PMID 22995123 DOI: 10.1186/1742-4690-9-76  0.528
2012 Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England Journal of Medicine. 366: 1275-86. PMID 22475592 DOI: 10.1056/Nejmoa1113425  0.452
2012 Rao M, Karasavvas N, Pinter A, Liao H, Bonsignori M, Mathieson B, Zolla-Pazner S, Haynes B, Michael N, Kim J, Alving C, Peachman K. Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-P71  0.569
2012 Pinter A, Wu A, Neubert T, Burkhart M, Honnen W. Conformational heterogeneity in V1/V2 domain affects the immunological properties of this region Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-P307  0.496
2012 Theis J, de Parseval A, Honnen W, Phogat A, Ganapathi U, Lai Z, Peng L, Reichman C, Moore P, Morris L, Li Y, Hu S, Pinter A. Construction of SHIVs expressing quaternary neutralization epitopes in Env and mimicking the neutralization phenotype of typical HIV-1 isolates Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-P28  0.45
2012 Liao L, Bonsignori M, Hwang K, Moody A, Park R, Crawford S, Chen H, Jeffries T, Cooper M, Lu X, De R, Karasavvas N, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, ... ... Pinter A, et al. Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-O31  0.46
2012 Krachmarov C, Revesz K, Prattipati R, Reichman C, Li B, Derdeyn C, Sarlo J, Zingman B, Honnen W, Pinter A. Characterization of V1/V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-O30  0.586
2012 Krachmarov C, Revesz K, Prattipati R, Reichman C, Lai Z, Honnen W, Li B, Derdeyn C, Pinter A. Characterization of V1V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-O30  0.405
2011 Krachmarov C, Lai Z, Honnen WJ, Salomon A, Gorny MK, Zolla-Pazner S, Robinson J, Pinter A. Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities. Journal of Virology. 85: 10730-40. PMID 21835798 DOI: 10.1128/Jvi.00365-11  0.448
2011 Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. Journal of Virology. 85: 3128-41. PMID 21270156 DOI: 10.1128/Jvi.02658-10  0.485
2011 Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, Williams C, Seaman MS, Abagyan R, Cardozo T, Gorny MK, Wang S, Lu S, Pinter A, Zolla-Pazner S. Corrigendum to Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold" [Virology 351 (2010) 513-523] Virology. 409: 360. DOI: 10.1016/J.Virol.2010.11.003  0.423
2010 Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, Williams C, Seaman MS, Abagyan R, Cardozo T, Gorny MK, Wang S, Lu S, Pinter A, Zolla-Pazner S. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology. 405: 513-23. PMID 20663531 DOI: 10.1016/J.Virol.2010.06.027  0.482
2010 Lynch RM, Rong R, Li B, Shen T, Honnen W, Mulenga J, Allen S, Pinter A, Gnanakaran S, Derdeyn CA. Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. Virology. 404: 59-70. PMID 20494390 DOI: 10.1016/J.Virol.2010.04.010  0.46
2009 Granados-Gonzalez V, Piedrahita LD, Martinez-Gutierrez M, Lawrence P, Saoudin H, Zapata X, Lucht F, Pinter A, Genin C, Urcuqui-Inchima S, Riffard S. Neutralizing inter-clade cross-reactivity of HIV-1 V1/V2-specific secretory immunoglobulin A in Colombian and French cohorts. Aids (London, England). 23: 2219-22. PMID 19830891  0.498
2009 Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE, Gnanakaran S, Derdeyn CA. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. Plos Pathogens. 5: e1000594. PMID 19763269 DOI: 10.1371/Journal.Ppat.1000594  0.576
2009 Zolla-Pazner S, Cohen S, Pinter A, Krachmarov C, Wrin T, Wang S, Lu S. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology. 392: 82-93. PMID 19632700 DOI: 10.1016/J.Virol.2009.05.039  0.458
2009 Cardozo T, Swetnam J, Pinter A, Krachmarov C, Nadas A, Almond D, Zolla-Pazner S. Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. Aids Research and Human Retroviruses. 25: 441-50. PMID 19320565 DOI: 10.1089/Aid.2008.0188  0.605
2009 Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology. 387: 414-26. PMID 19298995 DOI: 10.1016/J.Virol.2009.02.022  0.569
2009 Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. Journal of Virology. 83: 1240-59. PMID 19019969 DOI: 10.1128/Jvi.01743-08  0.57
2009 Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S, Nadas A. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Molecular Immunology. 46: 917-26. PMID 18952295 DOI: 10.1016/J.Molimm.2008.09.005  0.499
2009 Zolla-Pazner S, Kong X, Cardozo T, Hioe C, Cohen S, Jiang X, Gorny MK, Totrov M, Pinter A, Krachmarov C, Seaman MS, Wang S, Lu S. P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope Retrovirology. 6: P37. DOI: 10.1186/1742-4690-6-S3-P37  0.445
2009 Totrov M, Jiang X, Kong X, Cohen S, Krachmarov C, Williams C, Cardozo T, Gorny M, Wang S, Lu S, Pinter A, Zolla-Pazner S. P12-13. Structure-guided design and immunological characterization of immunogen constructs presenting the HIV-1 gp120 V3 loop on a CTB scaffold Retrovirology. 6: P179. DOI: 10.1186/1742-4690-6-S3-P179  0.497
2009 Rong R, Li B, Haaland RE, Murphy MK, Mulenga J, Allen SA, Blackwell JL, Pinter A, Shaw GM, Gnanakaran S, Hunter E, Robinson JE, Derdeyn CA. P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape Retrovirology. 6: P125. DOI: 10.1186/1742-4690-6-S3-P125  0.355
2009 Zolla-Pazner S, Cohen S, Krachmarov C, Pinter A, Wang S, Lu S. 171 Induction of Cross-clade Neutralizing Antibodies in Rabbits Using a DNA Prime/Protein Boost Immunization Regimen Jaids Journal of Acquired Immune Deficiency Syndromes. 51: 1. DOI: 10.1097/01.Qai.0000351131.71782.2E  0.36
2008 Granados-Gonzalez V, Claret J, Berlier W, Vincent N, Urcuqui-Inchima S, Lucht F, Defontaine C, Pinter A, Genin C, Riffard S. Opposite immune reactivity of serum IgG and secretory IgA to conformational recombinant proteins mimicking V1/V2 domains of three different HIV type 1 subtypes depending on glycosylation. Aids Research and Human Retroviruses. 24: 289-99. PMID 18260782 DOI: 10.1089/Aid.2007.0187  0.585
2008 Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, Lu S. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology. 372: 233-46. PMID 18061228 DOI: 10.1016/J.Virol.2007.09.024  0.438
2007 Wilkinson RA, Evans JR, Jacobs JM, Slunaker D, Pincus SH, Pinter A, Parkos CA, Burritt JB, Teintze M. Peptides selected from a phage display library with an HIV-neutralizing antibody elicit antibodies to HIV gp120 in rabbits, but not to the same epitope. Aids Research and Human Retroviruses. 23: 1416-27. PMID 18184085 DOI: 10.1089/Aid.2007.0027  0.561
2007 Pinter A. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. Current Hiv Research. 5: 542-53. PMID 18045110  0.349
2007 Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence Journal of Virology. 81: 1424-1432. PMID 17121806 DOI: 10.1128/Jvi.02054-06  0.581
2006 Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. Journal of Virology. 80: 7127-35. PMID 16809318 DOI: 10.1128/Jvi.02619-05  0.486
2006 Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Konings FA, Nádas A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. Journal of Virology. 80: 6865-72. PMID 16809292 DOI: 10.1128/Jvi.02202-05  0.466
2006 Zolla-Pazner S, Sharpe-Cohen S, Krachmarov C, Wang S, Pinter A, Lu S. Focusing the immune response on the V3 loop of HIV-1 gp120 induces cross-clade neutralizing Retrovirology. 3. DOI: 10.1186/1742-4690-3-S1-S23  0.512
2006 Pincus S, Jones S, Bradley T, Dunne J, Wang Q, Honnen W, Kunert R, Pinter A. A novel dual antibody conjugate (Heteropolymer) reduces circulating HIV in a mouse model Retrovirology. 3. DOI: 10.1186/1742-4690-3-S1-P76  0.539
2005 Tuen M, Visciano ML, Chien PC, Cohen S, Chen PD, Robinson J, He Y, Pinter A, Gorny MK, Hioe CE. Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. European Journal of Immunology. 35: 2541-51. PMID 16106369 DOI: 10.1002/Eji.200425859  0.529
2005 Burkhart MD, D'Agostino P, Kayman SC, Pinter A. Involvement of the C-terminal disulfide-bonded loop of murine leukemia virus SU protein in a postbinding step critical for viral entry. Journal of Virology. 79: 7868-76. PMID 15919941 DOI: 10.1128/Jvi.79.12.7868-7876.2005  0.743
2005 Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, Kayman SC. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. Journal of Virology. 79: 6909-17. PMID 15890930 DOI: 10.1128/Jvi.79.11.6909-6917.2005  0.595
2005 Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, Zolla-Pazner S, Kayman SC. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. Journal of Virology. 79: 780-90. PMID 15613306 DOI: 10.1128/Jvi.79.2.780-790.2005  0.545
2004 Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. Journal of Virology. 78: 5205-15. PMID 15113902 DOI: 10.1128/Jvi.78.10.5205-5215.2004  0.621
2004 Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. Journal of Virology. 78: 2394-404. PMID 14963135 DOI: 10.1128/Jvi.78.5.2394-2404.2004  0.537
2003 He Y, D'Agostino P, Pinter A. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. Vaccine. 21: 4421-9. PMID 14505925 DOI: 10.1016/S0264-410X(03)00451-1  0.603
2003 Burkhart MD, Kayman SC, He Y, Pinter A. Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU. Journal of Virology. 77: 3993-4003. PMID 12634359 DOI: 10.1128/Jvi.77.7.3993-4003.2003  0.747
2002 Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. Journal of Virology. 76: 9035-45. PMID 12186887 DOI: 10.1128/Jvi.76.18.9035-9045.2002  0.587
2002 He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. Journal of Immunology (Baltimore, Md. : 1950). 169: 595-605. PMID 12077293 DOI: 10.4049/Jimmunol.169.1.595  0.772
2002 Krachmarov CP, Kayman SC, Honnen WJ, Trochev O, Pinter A. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. Aids Research and Human Retroviruses. 17: 1737-48. PMID 11788025 DOI: 10.1089/08892220152741432  0.604
1999 Kayman SC, Park H, Saxon M, Pinter A. The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system Journal of Virology. 73: 1802-1808. PMID 9971757 DOI: 10.1128/Jvi.73.3.1802-1808.1999  0.489
1999 Pinter A, Honnen WJ, Kayman SC, Trochev O, Wu Z. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine. 16: 1803-11. PMID 9795384 DOI: 10.1016/S0264-410X(98)00182-0  0.624
1999 Kayman SC, Park H, Saxon M, Pinter A. The Hypervariable Domain of the Murine Leukemia Virus Surface Protein Tolerates Large Insertions and Deletions, Enabling Development of a Retroviral Particle Display System Journal of Virology. 73: 1802-1808. DOI: 10.1128/jvi.73.3.1802-1808.1999  0.393
1998 Pincus SH, Cole RL, Watson-McKown R, Pinter A, Honnen W, Cole B, Wise KS. Immunologic cross-reaction between HIV type 1 p17 and Mycoplasma hyorhinis variable lipoprotein. Aids Research and Human Retroviruses. 14: 419-25. PMID 9546801 DOI: 10.1089/Aid.1998.14.419  0.538
1997 Li Z, Pinter A, Kayman SC. The critical N-linked glycan of murine leukemia virus envelope protein promotes both folding of the C-terminal domains of the precursor polyprotein and stability of the postcleavage envelope complex. Journal of Virology. 71: 7012-7019. DOI: 10.1128/jvi.71.9.7012-7019.1997  0.316
1997 Alsmadi O, Herz R, Murphy E, Pinter A, Tilley SA. A novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infection. Journal of Virology. 71: 925-933. DOI: 10.1128/Jvi.71.2.925-933.1997  0.489
1996 Pincus SH, Wehrly K, Cole R, Fang H, Lewis GK, McClure J, Conley AJ, Wahren B, Posner MR, Notkins AL, Tilley SA, Pinter A, Eiden L, Teintze M, Dorward D, et al. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160 Aids Research and Human Retroviruses. 12: 1041-1051. PMID 8827220 DOI: 10.1089/Aid.1996.12.1041  0.569
1996 Vijh-Warrier S, Pinter A, Honnen WJ, Tilley SA. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. Journal of Virology. 70: 4466-4473. DOI: 10.1128/Jvi.70.7.4466-4473.1996  0.587
1995 Demaria S, Tilley SA, Pinter A, Bushkin Y. Bathophenanthroline disulfonate and soluble CD4 as probes for early events of HIV type 1 entry. Aids Research and Human Retroviruses. 11: 127-39. PMID 7734186 DOI: 10.1089/Aid.1995.11.127  0.51
1995 Wu Z, Kayman SC, Honnen W, Revesz K, Chen H, Vijh-Warrier S, Tilley SA, McKeating J, Shotton C, Pinter A. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. Journal of Virology. 69: 2271-2278. DOI: 10.1128/Jvi.69.4.2271-2278.1995  0.553
1994 Murphy E, Korber B, Georges-Courbot MC, You B, Pinter A, Cook D, Kieny MP, Georges A, Mathiot C, Barré-Sinoussi F. Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. Aids Research and Human Retroviruses. 9: 997-1006. PMID 8280481 DOI: 10.1089/Aid.1993.9.997  0.408
1994 Battini JL, Kayman SC, Pinter A, Heard JM, Danos O. Role of N-linked glycosylation in the activity of the Friend murine leukemia virus SU protein receptor-binding domain. Virology. 202: 496-9. PMID 8009864 DOI: 10.1006/Viro.1994.1369  0.439
1994 Pinter A, Honnen WJ, Racho ME, Tilley SA. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. Aids Research and Human Retroviruses. 9: 985-96. PMID 7506556 DOI: 10.1089/Aid.1993.9.985  0.509
1994 Kayman SC, Wu Z, Revesz K, Chen H, Kopelman R, Pinter A. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. Journal of Virology. 68: 400-10. PMID 7504740 DOI: 10.1128/Jvi.68.1.400-410.1994  0.607
1994 Warrier SV, Pinter A, Honnen WJ, Girard M, Muchmore E, Tilley SA. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. Journal of Virology. 68: 4636-4642. DOI: 10.1128/Jvi.68.7.4636-4642.1994  0.656
1993 Pinter A, Honnen WJ, Revesz K, Herz R. Identification of large glycosylated proteins recognized by monoclonal antibodies against HIV-1 gag proteins. Aids Research and Human Retroviruses. 8: 1341-4. PMID 1466953 DOI: 10.1089/Aid.1992.8.1341  0.497
1993 Pinter A, Honnen WJ, Tilley SA. Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites. Journal of Virology. 67: 5692-5697. DOI: 10.1128/Jvi.67.9.5692-5697.1993  0.53
1993 Wang Y, Kayman SC, Li JP, Pinter A. Erythropoietin receptor (EpoR)-dependent mitogenicity of spleen focus-forming virus correlates with viral pathogenicity and processing of env protein but not with formation of gp52-EpoR complexes in the endoplasmic reticulum. Journal of Virology. 67: 1322-1327. DOI: 10.1128/Jvi.67.3.1322-1327.1993  0.397
1992 Tilley SA, Honnen WJ, Racho ME, Hilgartner M, Pinter A. A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. Research in Virology. 142: 247-59. PMID 1724568 DOI: 10.1016/0923-2516(91)90010-Z  0.559
1992 Ronco J, Dedieu JF, Marie FN, Pinter A, Kaczorek M, Girard M. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides. Aids Research and Human Retroviruses. 8: 1117-23. PMID 1503824 DOI: 10.1089/Aid.1992.8.1117  0.514
1992 Tilley SA, Honnen WJ, Racho ME, Chou TC, Pinter A. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. Aids Research and Human Retroviruses. 8: 461-7. PMID 1376135 DOI: 10.1089/Aid.1992.8.461  0.577
1992 Thali M, Furman C, Ho DD, Robinson J, Tilley S, Pinter A, Sodroski J. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. Journal of Virology. 66: 5635-5641. DOI: 10.1128/Jvi.66.9.5635-5641.1992  0.545
1992 Wyatt R, Thali M, Tilley S, Pinter A, Posner M, Ho D, Robinson J, Sodroski J. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. Journal of Virology. 66: 6997-7004. DOI: 10.1128/Jvi.66.12.6997-7004.1992  0.524
1991 Girard M, Kieny MP, Pinter A, Barre-Sinoussi F, Nara P, Kolbe H, Kusumi K, Chaput A, Reinhart T, Muchmore E, Ronco J, Kaczorek M, Gomard E, Gluckman JC, Fultz PN. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus Proceedings of the National Academy of Sciences of the United States of America. 88: 542-546. PMID 1988952 DOI: 10.1073/Pnas.88.2.542  0.449
1991 Kayman SC, Kopelman R, Projan S, Kinney DM, Pinter A. Mutational analysis of N-linked glycosylation sites of Friend murine leukemia virus envelope protein. Journal of Virology. 65: 5323-32. PMID 1895386 DOI: 10.1128/Jvi.65.10.5323-5332.1991  0.399
1991 Shang F, Huang H, Revesz K, Chen HC, Herz R, Pinter A. Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells. Journal of Virology. 65: 4798-4804. DOI: 10.1128/Jvi.65.9.4798-4804.1991  0.58
1991 Hong T, Drlica K, Pinter A, Murphy E. Circular DNA of human immunodeficiency virus: analysis of circle junction nucleotide sequences. Journal of Virology. 65: 551-555. DOI: 10.1128/Jvi.65.1.551-555.1991  0.407
1989 Pinter A, Honnen WJ. Biochemical characterization of cell-associated and extracellular products of the Friend spleen focus-forming virus env gene. Virology. 173: 136-43. PMID 2554567 DOI: 10.1016/0042-6822(89)90229-8  0.38
1989 Pinter A, Honnen WJ, Tilley SA, Bona C, Zaghouani H, Gorny MK, Zolla-Pazner S. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. Journal of Virology. 63: 2674-2679. DOI: 10.1128/Jvi.63.6.2674-2679.1989  0.495
1988 Pinter A, Honnen WJ. A sensitive radioimmunoprecipitation assay for human immunodeficiency virus (HIV). Journal of Immunological Methods. 112: 235-41. PMID 3418129 DOI: 10.1016/0022-1759(88)90363-8  0.521
1988 Pinter A, Honnen WJ. O-linked glycosylation of retroviral envelope gene products. Journal of Virology. 62: 1016-1021. DOI: 10.1128/Jvi.62.3.1016-1021.1988  0.338
1987 Zolla-Pazner S, Pinter A, Mizuma H. Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus. Journal of Virological Methods. 17: 45-53. PMID 3312267 DOI: 10.1016/0166-0934(87)90067-X  0.439
1984 Pinter A, Honnen WJ. Characterization of structural and immunological properties of specific domains of Friend ecotropic and dual-tropic murine leukemia virus gp70s. Journal of Virology. 49: 452-458. DOI: 10.1128/jvi.49.2.452-458.1984  0.348
1983 Pinter A, Honnen WJ. Comparison of structural domains of gp70s of ecotropic Akv and dualtropic MCF-247 MuLVs. Virology. 129: 40-50. PMID 6310885 DOI: 10.1016/0042-6822(83)90394-X  0.362
1982 Pinter A, Honnen WJ, Tung JS, O'Donnell PV, Hämmerling U. Structural domains of endogenous murine leukemia virus gp70s containing specific antigenic determinants defined by monoclonal antibodies. Virology. 116: 499-516. PMID 6175079 DOI: 10.1016/0042-6822(82)90143-X  0.429
1981 Pierotti M, DeLeo AB, Pinter A, O'Donnell PV, Hämmerling U, Fleissner E. The GIX antigen of murine leukemia virus: an analysis with monoclonal antibodies. Virology. 112: 450-60. PMID 6167060 DOI: 10.1016/0042-6822(81)90292-0  0.337
1981 Nowinski RC, Pickering R, O'Donnell PV, Pinter A, Hammerling U. Selective neutralization of ecotropic murine leukemia virus by monoclonal antibodies: localization of a site on the gp70 protein associated with ecotropism. Virology. 111: 84-92. PMID 6165138 DOI: 10.1016/0042-6822(81)90655-3  0.351
1980 Lostrom ME, Stone MR, Tam M, Burnette WN, Pinter A, Nowinski RC. Monoclonal antibodies against murine leukemia viruses: identification of six antigenic determinants on the p 15(E) and gp70 envelope proteins. Virology. 98: 336-50. PMID 92097 DOI: 10.1016/0042-6822(79)90557-9  0.351
Show low-probability matches.